In 2020, amid the COVID-19 pandemic and a rise in "reshoring" sentiment in the U.S., Hester Pharmaceuticals had to decide whether to build a new plant for its new oncology drug Akrozumab in Germany or in the U.S., or whether it should hire a contract manufacturing organization (CMO) to produce the drug.